Martin Tallman MD

PubMed

• Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.
  Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, Jessica K Altman, Rahul K Thakur
  Blood Advances. 2026-03-10
• Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
  Tamar Tadmor, Judit Demeter, Andrei Fagarasanu, Robert J Kreitman, Sameer A Parikh
  Leukemia & Lymphoma. 2025-12-01
• Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant.
  Susan DeWolf, Jason Kuttiyara, Paola Vinci, Teng Fei, John Slingerland
  Blood Advances. 2025-10-28

Journal Articles

• Extramedullary Acute Myeloid Leukemia Presenting in Young Adults Demonstrates Sensitivity to High Dose Anthracycline: Subset Analysis from ECOG-ACRIN 1900  
  Selina M Luger, Ross L Levine, Martin S Tallman, Haematologica
• Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
  Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Abstracts/Posters

• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

• Clinical features and diagnosis of hairy cell leukemia 
  Tallman MS, Aster JC
  http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-hairy-cell-leukemia
  UpToDate, Wolters Kluwer Health - 2013-04-02
• Treatment of hairy cell leukemia 
  Tallman MS
  http://www.uptodate.com/contents/treatment-of-hairy-cell-leukemia
  UpToDate, Wolters Kluwer Health - 2012-12-12